Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Description

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of semaglutide 2.0 mg (Ozempic)'s approval, the use of novel glycemic control metrics, and a preview of ATTD 2022.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.